Literature DB >> 14667958

A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture.

Palle Mark Christensen1, Kim Brosen, Kim Brixen, Morten Andersen, Ivar Sønbø Kristiansen.   

Abstract

BACKGROUND: Information on the benefits of therapeutic interventions can be ex-pressed in various ways, including relative risk reduction, absolute risk reduction,and number needed to treat (NNT). An alternative to such risk-based measures is postponement of an adverse outcome (eg, hip fracture in the case of osteoporosis).
OBJECTIVE: The goal of this study was to examine whether laypersons' perception of the benefit of an osteoporosis therapy differs when it is presented in terms of the NNT to avoid 1 hip fracture compared with the duration of postponement of hip fracture.
METHODS: This was a cross-sectional, randomized, controlled trial. Face-to-face interviews of a representative sample of the Danish population were conducted in respondents' homes. Respondents were randomized to receive information about the benefits of a hypothetical osteoporosis intervention either in terms of different magnitudes of NNT (10, 50, 100, or 400) or different durations of postponement of hip fracture (1 month, 6 months, 1 year, or 4 years). Participants were subsequently asked if they would consent to the intervention.
RESULTS: A total of 1728 individuals were contacted at home and asked if they would take part in a face-to-face interview; 967 (56%) were successfully interviewed. The age (mean age, 44.5 years; range, 20-74 years) and sex distribution (51% male, 50% female) of the sample was similar to that of the general Danish population. Based on NNTs of 10, 50, 100, and 400, the proportions of respondents who said they would consent to the intervention were a respective 65%,61%, 63%, and 57%. Increasing NNT was not significantly associated with a lower proportion of consent (test for trend chi-square(1)= 0.75; P = NS). Forty-three percent of respondents indicated that the concept of NNT was difficult to understand, and 38% interpreted NNT in a way that was probably incorrect. In terms of postponement of hip fracture by 1 month, 6 months, 1 year, and 4 years, the proportions who said they would consent to the intervention were a respective 25%, 40%, 39%, and 53%. Increasing postponement of hip fracture was significantly associated with higher proportions of consent (test for trend chi-square(1)= 20.09;P < 0.001). Logistic regression analysis found that consenting to therapy was inversely associated with age (NNT: OR, 0.83; 95% CI, 0.72-0.96; postponement of fracture: OR, 0.84; 95% CI, 0.73-0.98) and with the magnitude of benefit presented in terms of postponement of fracture. No other variables were significantly associated with consent to therapy.
CONCLUSIONS: When laypersons were presented with brief information about the benefit of a hypothetical osteoporosis intervention and were then offered this therapy, their choices were sensitive to the magnitude of treatment benefit when it was presented in terms of postponement of hip fracture but not in terms of NNT. These findings suggest that it may be easier for laypersons to understand a potential treatment benefit in terms of postponement of fracture rather than NNT.

Entities:  

Mesh:

Year:  2003        PMID: 14667958     DOI: 10.1016/s0149-2918(03)80318-1

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  15 in total

1.  Evaluation of benefit-risk.

Authors:  Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl
Journal:  Br J Gen Pract       Date:  2014-04       Impact factor: 5.386

3.  Therapeutic decisions by number needed to treat and survival gains: a cross-sectional survey of lipid-lowering drug recommendations.

Authors:  Peder A Halvorsen; Torbjørn F Wisløff; Henrik Støvring; Olaf Aasland; Ivar Sønbø Kristiansen
Journal:  Br J Gen Pract       Date:  2011-08       Impact factor: 5.386

4.  Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Morten Rix Hansen; Asbjørn Hróbjartsson; Anton Pottegård; Per Damkier; Kasper Søltoft Larsen; Kenneth Grønkjær Madsen; René dePont Christensen; Malene Elisa Lopez Kristensen; Palle Mark Christensen; Jesper Hallas
Journal:  J Gen Intern Med       Date:  2019-05-09       Impact factor: 5.128

5.  Development of life-expectancy tables for people with type 2 diabetes.

Authors:  Jose Leal; Alastair M Gray; Philip M Clarke
Journal:  Eur Heart J       Date:  2008-12-24       Impact factor: 29.983

Review 6.  The effect of statins on average survival in randomised trials, an analysis of end point postponement.

Authors:  Malene Lopez Kristensen; Palle Mark Christensen; Jesper Hallas
Journal:  BMJ Open       Date:  2015-09-24       Impact factor: 2.692

7.  Communicating study results to our patients: which way is best?

Authors:  B A Petrisor; Paul Tornetta
Journal:  Indian J Orthop       Date:  2008-04       Impact factor: 1.251

8.  Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the "Influence of intervention Methodologies on Patient Choice of Therapy (IMPACT)" cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Dorte Ejg Jarbøl; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Health Serv Res       Date:  2013-02-25       Impact factor: 2.655

9.  Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey.

Authors:  Rasmus Dahl; Dorte Gyrd-Hansen; Ivar Sønbø Kristiansen; Jørgen Nexøe; Jesper Bo Nielsen
Journal:  BMC Med Inform Decis Mak       Date:  2007-03-29       Impact factor: 2.796

10.  Laypersons' understanding of relative risk reductions: randomised cross-sectional study.

Authors:  Lene Sorensen; Dorte Gyrd-Hansen; Ivar S Kristiansen; Jørgen Nexøe; Jesper B Nielsen
Journal:  BMC Med Inform Decis Mak       Date:  2008-07-17       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.